A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

H0P-MC-NP05 -

This study is being done to test the safety and efficacy of the study drug LY3852710 for the treatment of diabetic peripheral neuropathic pain.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Diabetic Peripheral Neuropathic Pain, Chronic Pain
What the trial is testing?
LY3852710
Could I receive a Placebo?
Yes
Enrollment Goal
131
Trial Dates
Nov 14, 2022 - Aug 1, 2023
How long will I be in the trial?
The study will last about 12 weeks and may include up to 8 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have daily pain for at least 12 weeks

  • Participants must be willing to maintain any non-drug pain relieving therapies (for example, physical therapy) and not start any new non-drug pain-relieving therapies during the study

  • Participants must be willing to stop all pain medications for diabetic nerve pain, except for rescue medication allowed in the study

  • Participants must have type 1 or type 2 diabetes and stable glycemic control

Participants Must Not:

  • Participants must not have surgery planned during the study for any reason

  • Participants must not have an intolerance to acetaminophen or paracetamol

  • Participants must not have a history of alcohol or drug disorder within 2 years

  • Participants must not have a current drug-induced neuropathy, for example, due to some types of chemotherapy, or other types of peripheral neuropathy

  • Have a seizure disorder or history of seizure

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources